{"created":"2024-12-12T10:18:10.921339+00:00","id":2011400,"links":{},"metadata":{"_buckets":{"deposit":"44004238-3964-4b37-baa1-3a1de88b7103"},"_deposit":{"created_by":7,"id":"2011400","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2011400"},"status":"published"},"_oai":{"id":"oai:tokushima-u.repo.nii.ac.jp:02011400","sets":["1713853213384:1713853295607"]},"author_link":["415"],"control_number":"2011400","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-02-21","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"689","bibliographicPageStart":"671","bibliographicVolumeNumber":"14","bibliographic_titles":[{"bibliographic_title":"Diabetes Therapy","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Introduction: iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, is one option for treatment intensification in individuals with type 2 diabetes (T2D) who are unable to achieve targeted glycaemic control with their current glucose-lowering agent. Real-world data on the impact of prior treatment on the effectiveness and safety of iGlarLixi may be useful to guide individualised treatment decisions.\nMethods: This analysis of the 6-month, retrospective, observational SPARTA Japan study compared glycated haemoglobin (HbA1c), body weight and safety for pre-specified subgroups defined by prior treatment: post oral antidiabetic agent (OAD), GLP-1 RA, basal insulin (BI) + OADs (BOT), GLP-1 RA + BI or multiple daily injections (MDI). The post BOT and MDI subgroups were further divided on the basis of prior dipeptidyl peptidase 4 inhibitor (DPP-4i) use, and the post MDI group was divided on the basis of whether participants continued bolus insulin.\nResults: Of the 432 participants in the full analysis set (FAS), 337 were included in this subgroup analysis. Across subgroups, mean baseline HbA1c ranged from 8.49% to 9.18%. iGlarLixi significantly (p < 0.05) reduced mean HbA1c from baseline in all but the post GLP-1 RA + BI group. At 6 months, these significant reductions ranged from 0.47% to 1.27%. Prior DPP-4i exposure had no impact on the HbA1c-lowering effect of iGlarLixi. Mean body weight decreased significantly in the FAS (0.5 kg) and the post BOT (1.2 kg) and MDI (1.5 and 1.9 kg) subgroups but increased in the post GLP-1 RA subgroup (1.3 kg). iGlarLixi treatment was generally well tolerated, with very few participants discontinuing because of hypoglycaemia or gastrointestinal events.\nConclusion: In participants with suboptimal glycaemic control on various regimens, 6 months of iGlarLixi treatment improved HbA1c in all but one prior treatment subgroup (GLP-1 RA + BI), and was generally well tolerated.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Nature","subitem_publisher_language":"en"}]},"item_10001_rights_15":{"attribute_name":"権利情報","attribute_value_mlt":[{"subitem_rights":"This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.","subitem_rights_language":"en"}]},"item_10001_source_id_9":{"attribute_name":"収録物ID","attribute_value_mlt":[{"subitem_source_identifier":"18696961","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"18696953","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1715043197608":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access"}]},"item_1722929371688":{"attribute_name":"出版社版DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_language":"ja","subitem_relation_name_text":"10.1007/s13300-023-01373-w"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s13300-023-01373-w","subitem_relation_type_select":"DOI"}}]},"item_1723180141928":{"attribute_name":"EID","attribute_value_mlt":[{"subitem_identifier_type":"URI","subitem_identifier_uri":"399423"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ミヨシ, ヒデアキ","creatorNameLang":"ja"},{"creatorName":"ミヨシ, ヒデアキ","creatorNameLang":"ja-Kana"},{"creatorName":"Miyoshi, Hideaki","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"松久, 宗英","creatorNameLang":"ja"},{"creatorName":"マツヒサ, ムネヒデ","creatorNameLang":"ja-Kana"},{"creatorName":"Matsuhisa, Munehide","creatorNameLang":"en"}],"familyNames":[{"familyName":"松久","familyNameLang":"ja"},{"familyName":"マツヒサ","familyNameLang":"ja-Kana"},{"familyName":"Matsuhisa","familyNameLang":"en"}],"givenNames":[{"givenName":"宗英","givenNameLang":"ja"},{"givenName":"ムネヒデ","givenNameLang":"ja-Kana"},{"givenName":"Munehide","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"415","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"205776/profile-ja.html","nameIdentifierScheme":"徳島大学 教育研究者総覧","nameIdentifierURI":"http://pub2.db.tokushima-u.ac.jp/ERD/person/205776/profile-ja.html"},{"nameIdentifier":"60362737","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?qm=60362737"}]},{"creatorNames":[{"creatorName":"ヤベ, ダイスケ","creatorNameLang":"ja"},{"creatorName":"ヤベ, ダイスケ","creatorNameLang":"ja-Kana"},{"creatorName":"Yabe, Daisuke","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"タカハシ, ヨウコ","creatorNameLang":"ja"},{"creatorName":"タカハシ, ヨウコ","creatorNameLang":"ja-Kana"},{"creatorName":"Takahashi, Yoko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"モリモト, ユキコ","creatorNameLang":"ja"},{"creatorName":"モリモト, ユキコ","creatorNameLang":"ja-Kana"},{"creatorName":"Morimoto, Yukiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"テラウチ, ヤスオ","creatorNameLang":"ja"},{"creatorName":"テラウチ, ヤスオ","creatorNameLang":"ja-Kana"},{"creatorName":"Terauchi, Yasuo","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-11-22"}],"displaytype":"detail","filename":"dt_14_4_671.pdf","filesize":[{"value":"768 KB"}],"format":"application/pdf","licensetype":"license_3","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://tokushima-u.repo.nii.ac.jp/record/2011400/files/dt_14_4_671.pdf"},"version_id":"7ae0a531-3d0f-4481-84fd-1fe450ab930e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Fixed-ratio combination","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"iGlarLixi","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Insulin glargine","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Japan","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Lixisenatide","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Real-world data","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Type 2 diabetes mellitus","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice : Prior Treatment Subgroup Analysis of the SPARTA Japan Study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice : Prior Treatment Subgroup Analysis of the SPARTA Japan Study","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"7","path":["1713853295607"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-11-22"},"publish_date":"2023-11-22","publish_status":"0","recid":"2011400","relation_version_is_last":true,"title":["Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice : Prior Treatment Subgroup Analysis of the SPARTA Japan Study"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2025-01-29T07:18:43.718552+00:00"}